A Prospective, Open-Label, Single-Arm, Single-Center Study To Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) And Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of Thrombosis

Trial Profile

A Prospective, Open-Label, Single-Arm, Single-Center Study To Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) And Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of Thrombosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Cangrelor (Primary)
  • Indications Coronary thrombosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Chiesi USA
  • Most Recent Events

    • 10 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Jan 2018.
    • 10 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 Jan 2018.
    • 10 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top